司美格鲁肽获批治疗MASH

Core Viewpoint - Novo Nordisk announced the FDA approval of a supplemental new drug application (sNDA) for semaglutide (Wegovy) to treat metabolic dysfunction-associated fatty liver disease (MAFLD) in patients with moderate to advanced liver fibrosis (F2 or F3) [1] Group 1 - The accelerated approval is based on data from the ESSENCE clinical trial [1] - The treatment group showed significant improvement in liver fibrosis without worsening of fatty liver disease [1] - Fatty liver disease was alleviated without deterioration of liver fibrosis [1]